June 6, 2025

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring 183.86% Upside Potential in the Biotech Sector

Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, is making waves in the healthcare sector with a focus on innovative solutions..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: A Biotech Player with 113.86% Potential Upside

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is attracting attention in the biotech sector with its promising pipeline of treatments for neurodegenerative diseases and endocrine conditions. Based in..

Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating Challenges and Opportunities in the Healthcare Sector

Avanos Medical, Inc. (NYSE: AVNS), a key player in the medical devices industry, is currently navigating a challenging landscape. With a market capitalization of $570.19 million,..

Surmodics, Inc. (SRDX) Stock Analysis: Navigating a 44% Potential Upside Amid Revenue Challenges

Surmodics, Inc. (NASDAQ: SRDX), a prominent player in the healthcare sector specializing in medical devices, stands out in the marketplace with a distinct proposition. Based in..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Unlocking a 39.83% Potential Upside

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is capturing investor attention with its significant potential upside of 39.83%. As a specialty pharmaceutical company focusing on pain management treatments,..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating a 24% Potential Upside Amidst Biotechnology Challenges

For investors eyeing the biotechnology sector, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) presents a compelling, albeit challenging, proposition. With a market capitalization of $423.19 million, Ginkgo..

Septerna, Inc. (SEPN) Stock Analysis: Exploring a 124.97% Potential Upside in the Biotechnology Sector

Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company headquartered in South San Francisco, is making waves in the healthcare sector with its innovative approach to treating..

Bioventus Inc. (BVS) Stock Analysis: Exploring a Potential 89% Upside in the Medical Devices Sector

Bioventus Inc. (NASDAQ: BVS), a prominent name in the healthcare sector, specializes in medical devices aimed at pain relief and musculoskeletal therapies. Headquartered in Durham, North..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Unveiling a 132.98% Potential Upside Amidst Challenges

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) operates at the intersection of biotechnology and healthcare, providing key products that facilitate the development of drug therapies, vaccines, and..

Verve Therapeutics, Inc. (VERV) Stock Analysis: Unveiling a Potential 324.67% Upside in the Biotech Sector

Verve Therapeutics, Inc. (NASDAQ: VERV) has been making waves within the biotechnology industry, offering investors a thrilling opportunity with a potential upside of 324.67%, according to..

Standard BioTools Inc. (LAB) Stock Analysis: Navigating a 138.96% Potential Upside in the Medical Devices Sector

Standard BioTools Inc. (NASDAQ: LAB) is capturing investor attention with its significant potential upside, pegged at 138.96%. As a key player in the medical devices sector,..

Humacyte, Inc. (HUMA) Stock Analysis: Uncovering a Potential 259.87% Upside in the Biotechnology Arena

Humacyte, Inc. (NASDAQ: HUMA), a pioneering entity in the biotechnology sector, is capturing the attention of investors with its innovative approach to developing bioengineered human tissues...

MeiraGTx Holdings plc (MGTX) Stock Analysis: A High-Stakes Bet with 319.71% Potential Upside

For investors with a penchant for high-risk, high-reward opportunities, MeiraGTx Holdings plc (NASDAQ: MGTX) presents an intriguing case. This clinical-stage gene therapy company, focused on treating..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Biotech Gem with 224% Potential Upside

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is making waves in the biotechnology sector with its promising therapeutic developments and compelling stock potential. As a clinical-stage biopharmaceutical company,..

KalVista Pharmaceuticals, Inc. (KALV): Investor Outlook on a Potential 91.63% Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is drawing significant attention from investors eager to tap into the potential upside of 91.63% suggested by its current average analyst..

Castle Biosciences, Inc. (CSTL) Stock Analysis: Unlocking a 110.86% Potential Upside in the Healthcare Diagnostics Sector

Castle Biosciences, Inc. (NASDAQ: CSTL), a prominent player in the healthcare sector focusing on molecular diagnostics, is capturing significant attention from investors seeking substantial growth opportunities...

HealthStream, Inc. (HSTM) Stock Analysis: Exploring 21.91% Potential Upside in the Healthcare SaaS Sector

HealthStream, Inc. (NASDAQ: HSTM) stands as a notable player in the health information services industry, delivering essential Software-as-a-Service (SaaS) solutions to healthcare organizations across the United..

Opthea Limited (OPT) Stock Analysis: Navigating the Biotech Waters with a Bold Vision in Eye Disease Treatment

Opthea Limited (ASX: OPT), an Australian biotechnology company, is making waves in the healthcare sector with its pioneering approach to treating eye diseases. As a clinical-stage..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Promising 76.48% Upside Potential for Biotech Investors

Enliven Therapeutics, Inc. (ELVN), a burgeoning name in the biotechnology industry, presents a compelling opportunity for investors seeking exposure to the healthcare sector. With a market..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 103% Upside Potential in Biotechnology

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is making waves in the biotechnology sector, presenting a compelling opportunity for investors seeking exposure to cutting-edge cancer therapies. With a..

Search

Funds

June 6, 2025

Search

Funds

June 6, 2025

FTSE 100

Funds